These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23083787)

  • 1. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).
    Vardeny O; Wu DH; Desai A; Rossignol P; Zannad F; Pitt B; Solomon SD;
    J Am Coll Cardiol; 2012 Nov; 60(20):2082-9. PubMed ID: 23083787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy.
    Maeder MT; Rickli H; Pfisterer ME; Muzzarelli S; Ammann P; Fehr T; Hack D; Weilenmann D; Dieterle T; Kiencke S; Estlinbaum W; Brunner-La Rocca HP;
    Am Heart J; 2012 Mar; 163(3):407-14, 414.e1. PubMed ID: 22424011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A; Cohn JN; Latini R; Tognoni G; Krum H; Massie B; Zalewski A; Kandra A; Hua TA; Gimpelewicz C
    Eur J Heart Fail; 2013 Nov; 15(11):1236-44. PubMed ID: 23787721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.
    Blair JE; Pang PS; Schrier RW; Metra M; Traver B; Cook T; Campia U; Ambrosy A; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Konstam MA; Gheorghiade M;
    Eur Heart J; 2011 Oct; 32(20):2563-72. PubMed ID: 21785107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiorenal interactions: insights from the ESCAPE trial.
    Nohria A; Hasselblad V; Stebbins A; Pauly DF; Fonarow GC; Shah M; Yancy CW; Califf RM; Stevenson LW; Hill JA
    J Am Coll Cardiol; 2008 Apr; 51(13):1268-74. PubMed ID: 18371557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
    Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of worsening renal function related to medication in heart failure.
    Brunner-La Rocca HP; Knackstedt C; Eurlings L; Rolny V; Krause F; Pfisterer ME; Tobler D; Rickenbacher P; Maeder MT;
    Eur J Heart Fail; 2015 Feb; 17(2):159-68. PubMed ID: 25808849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.
    Masoudi FA; Gross CP; Wang Y; Rathore SS; Havranek EP; Foody JM; Krumholz HM
    Circulation; 2005 Jul; 112(1):39-47. PubMed ID: 15983243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
    Oh J; Kang SM; Song MK; Hong N; Youn JC; Han S; Jeon ES; Cho MC; Kim JJ; Yoo BS; Chae SC; Oh BH; Choi DJ; Lee MM; Ryu KH
    Am Heart J; 2015 May; 169(5):713-720.e3. PubMed ID: 25965719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of spironolactone in a specialized heart failure clinic.
    Sligl W; McAlister FA; Ezekowitz J; Armstrong PW
    Am J Cardiol; 2004 Aug; 94(4):443-7. PubMed ID: 15325926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
    Klein L; Massie BM; Leimberger JD; O'Connor CM; Piña IL; Adams KF; Califf RM; Gheorghiade M;
    Circ Heart Fail; 2008 May; 1(1):25-33. PubMed ID: 19808267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of the month. The RALES study (randomized aldactone evaluation study].
    Kulbertus H
    Rev Med Liege; 1999 Sep; 54(9):770-2. PubMed ID: 10589274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
    Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of worsening renal function during hospital admission on resource utilization in patients with heart failure.
    Herout PM; Harshaw Q; Phatak H; Saka G; McNeill A; Wu D; Sazonov V; DeSagun R; Shirani J
    Am J Cardiol; 2010 Oct; 106(8):1139-45. PubMed ID: 20920654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.